

Rui Providência

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1984380/publications.pdf>

Version: 2024-02-01

232
papers

6,151
citations

147801

31
h-index

85541

71
g-index

242
all docs

242
docs citations

242
times ranked

10021
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial experience of the High-Density Grid catheter in patients undergoing catheter ablation for atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 63, 259-266.	1.3	5
2	The use of remote monitoring of cardiac implantable devices during the COVID-19 pandemic: an EHRA physician survey. <i>Europace</i> , 2022, 24, 473-480.	1.7	32
3	An overview of heart rhythm disorders and management in myotonic dystrophy type 1. <i>Heart Rhythm</i> , 2022, 19, 497-504.	0.7	2
4	Catheter ablation for atrial fibrillation. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	0
5	Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases. <i>Drugs</i> , 2022, 82, 311.	10.9	12
6	Ethanol ablation for ventricular arrhythmias: A systematic review and meta-analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 510-526.	1.7	4
7	Long-term quality of life and acceptance of implantable cardioverter-defibrillator therapy: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2022, 24, 860-867.	1.7	14
8	Risk factors for developing pacing induced LV dysfunction: Experience from a tertiary center in the UK. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, .	1.2	0
9	Cardiopulmonary Resuscitation and Defibrillator Use in Sports. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 819609.	2.4	4
10	Is amiodarone still a reasonable therapeutic option for rhythm control in atrial fibrillation?. <i>Revista Portuguesa De Cardiologia</i> , 2022, 41, 783-789.	0.5	2
11	PolarX Cryoballoon metrics predicting successful pulmonary vein isolation: targets for ablation of atrial fibrillation. <i>Europace</i> , 2022, 24, 1420-1429.	1.7	7
12	Mexiletine for recurrent ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter defibrillator: an EHRA systematic review. <i>Europace</i> , 2022, 24, 1504-1511.	1.7	4
13	Quality indicators for the care and outcomes of adults with atrial fibrillation. <i>Europace</i> , 2021, 23, 494-495.	1.7	64
14	Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2021, 20, 30.	6.8	27
15	Ablation guided by STAR-mapping in addition to pulmonary vein isolation is superior to pulmonary vein isolation alone or in combination with CFAE/linear ablation for persistent AF. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 200-209.	1.7	2
16	OUP accepted manuscript. <i>Europace</i> , 2021, .	1.7	0
17	OUP accepted manuscript. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, .	4.0	2
18	High sensitivity troponin and COVID-19 outcomes. <i>Acta Cardiologica</i> , 2021, , 1-8.	0.9	16

#	ARTICLE	IF	CITATIONS
19	Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a European observational multicentre study. <i>Europace</i> , 2021, 23, 1409-1417.	1.7	16
20	Why We Are Losing the War Against COVID-19 on the Data Front and How to Reverse the Situation. <i>Jmirx Med</i> , 2021, 2, e20617.	0.4	8
21	Antithrombotic treatment management in low stroke risk patients undergoing cardioversion of atrial fibrillation <48 h duration: results of an EHRA survey. <i>Europace</i> , 2021, 23, 1502-1507.	1.7	2
22	Authors'™ Response to Peer Reviews of 'Why We Are Losing the War Against COVID-19 on the Data Front and How to Reverse the Situation' <i>Jmirx Med</i> , 2021, 2, e29421.	0.4	0
23	A multi-center experience of ablation index for evaluating lesion delivery in typical atrial flutter. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1039-1046.	1.2	4
24	Effectiveness and safety of a single freeze strategy of cryoballoon ablation of atrial fibrillation: an EHRA systematic review and meta-analysis. <i>Europace</i> , 2021, , .	1.7	9
25	A Normal Electrocardiogram Does Not Exclude Infra-Hisian Conduction Disease in Patients With Myotonic Dystrophy Type 1. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 1038-1048.	3.2	8
26	Long-Term Impact of Body Mass Index on Survival of Patients Undergoing Cardiac Resynchronization Therapy: A Multi-Centre Study. <i>American Journal of Cardiology</i> , 2021, 153, 79-85.	1.6	0
27	High-risk features and predictors of unexplained syncope in the young SCD-SOS cohort. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2737-2745.	1.7	2
28	Atrial fibrillation epidemiology, disparity and healthcare contacts: a population-wide study of 5.6 million individuals. <i>Lancet Regional Health - Europe, The</i> , 2021, 7, 100157.	5.6	23
29	Different methods of providing automatic external defibrillators to out-of-hospital cardiac arrests to prevent sudden cardiac death. <i>The Cochrane Library</i> , 2021, 2021, .	2.8	1
30	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013650.	2.8	28
31	Early mortality after implantable cardioverter defibrillator: Incidence and associated factors. <i>International Journal of Cardiology</i> , 2020, 301, 114-118.	1.7	5
32	Cryoablation for persistent and longstanding persistent atrial fibrillation: results from a multicentre European registry. <i>Europace</i> , 2020, 22, 375-381.	1.7	29
33	Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. <i>European Heart Journal</i> , 2020, 41, 1976-1986.	2.2	33
34	Epicardial Ablation in Brugada Syndrome. <i>Cardiac Electrophysiology Clinics</i> , 2020, 12, 345-356.	1.7	6
35	Same-day discharge following catheter ablation of atrial fibrillation: A safe and cost-effective approach. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 3097-3103.	1.7	27
36	Efficacy and safety of ablation index-guided catheter ablation for atrial fibrillation: an updated meta-analysis. <i>Europace</i> , 2020, 22, 1659-1671.	1.7	39

#	ARTICLE	IF	CITATIONS
37	Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation. The Cochrane Library, 2020, , .	2.8	0
38	Systematic review and network meta-analysis of atrial fibrillation percutaneous catheter ablation technologies using randomized controlled trials. Journal of Cardiovascular Electrophysiology, 2020, 31, 2192-2205.	1.7	4
39	Circulating Fatty Acids and Risk of Coronary Heart Disease and Stroke: Individual Participant Data Meta-Analysis in Up to 16126 Participants. Journal of the American Heart Association, 2020, 9, e013131.	3.7	36
40	Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease. Europace, 2020, 22, 1600-1600.	1.7	2
41	Non-vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2020, 31, 2626-2631.	1.7	6
42	Sex-specific efficacy and safety of cryoballoon versus radiofrequency ablation for atrial fibrillation: An individual patient data meta-analysis. Heart Rhythm, 2020, 17, 1232-1240.	0.7	11
43	Non-vitamin K oral anticoagulants at the time of cardiac rhythm device surgery: A systematic review and meta-analysis. Thrombosis Research, 2020, 188, 90-96.	1.7	7
44	Impact of pulmonary vein isolation on mechanisms sustaining persistent atrial fibrillation: Predicting the acute response. Journal of Cardiovascular Electrophysiology, 2020, 31, 903-912.	1.7	8
45	Impact of Type-2 Diabetes Mellitus on the Outcomes of Catheter Ablation of Atrial Fibrillation (European Observational Multicentre Study). American Journal of Cardiology, 2020, 125, 901-906.	1.6	30
46	Predictive Role of BNP/NT-proBNP in Non-Heart Failure Patients Undergoing Catheter Ablation for Atrial Fibrillation: An Updated Systematic Review. Current Medicinal Chemistry, 2020, 27, 4469-4478.	2.4	5
47	Ethnicity and COVID-19 cardiovascular complications: a multi-center UK cohort. American Journal of Cardiovascular Disease, 2020, 10, 455-462.	0.5	3
48	Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. Emergencias, 2020, 32, 57-58.	0.6	0
49	Structural remodeling and conduction velocity dynamics in the human left atrium: Relationship with reentrant mechanisms sustaining atrial fibrillation. Heart Rhythm, 2019, 16, 18-25.	0.7	42
50	Fluoroscopy guided axillary vein access versus cephalic vein access in pacemaker and defibrillator implantation: Randomized clinical trial of efficacy and safety. Journal of Cardiovascular Electrophysiology, 2019, 30, 2183-2183.	1.7	0
51	Science deserves justice: The results of the CABANA trial are positive and support catheter ablation of atrial fibrillation for reducing mortality and hospitalizations. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 245-250.	0.2	0
52	A nurse-led implantable loop recorder service is safe and cost effective. Journal of Cardiovascular Electrophysiology, 2019, 30, 2900-2906.	1.7	17
53	Impact of Ethnicity on the Prevalence of Early Repolarization Pattern in Children: Comparison Between Caucasian and African Populations. Pediatric Cardiology, 2019, 40, 1553-1558.	1.3	3
54	World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. The Lancet Global Health, 2019, 7, e1332-e1345.	6.3	554

#	ARTICLE	IF	CITATIONS
55	Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death in the real world: Main findings from the French multicentre DAI-PP programme (pilot phase). Archives of Cardiovascular Diseases, 2019, 112, 523-531.	1.6	1
56	Atrial Fibrillation Ablation and Reduction of Stroke Events. Stroke, 2019, 50, 2970-2976.	2.0	14
57	Full blood count as potential predictor of outcomes in patients undergoing cardiac resynchronization therapy. Scientific Reports, 2019, 9, 13016.	3.3	4
58	Impact of Body Mass Index on the Outcomes of Catheter Ablation of Atrial Fibrillation: A European Observational Multicenter Study. Journal of the American Heart Association, 2019, 8, e012253.	3.7	38
59	Catheter ablation of atrioventricular nodal re-entrant tachycardia: Humans versus machines?. Revista Portuguesa De Cardiologia, 2019, 38, 193-194.	0.5	0
60	Catheter ablation of atrioventricular nodal re-entrant tachycardia: Humans versus machines?. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 193-194.	0.2	0
61	Science deserves justice: The results of the CABANA trial are positive and support catheter ablation of atrial fibrillation for reducing mortality and hospitalizations. Revista Portuguesa De Cardiologia, 2019, 38, 245-250.	0.5	7
62	Catheter ablation of atrial fibrillation in patients with heart failure with reduced ejection fraction: Real world experience from six European centers. Journal of Cardiovascular Electrophysiology, 2019, 30, 1270-1277.	1.7	6
63	Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients. European Heart Journal, 2019, 40, 2121-2127.	2.2	29
64	Prolonged action potential duration and dynamic transmural action potential duration heterogeneity underlie vulnerability to ventricular tachycardia in patients undergoing ventricular tachycardia ablation. Europace, 2019, 21, 616-625.	1.7	17
65	P309R' wave in precordial leads V1-V2 in patients from the young SCD-SOS cohort. European Heart Journal, 2019, 40, .	2.2	0
66	Ventricular tachycardia ablation in structural heart disease: Impact of ablation strategy and non-inducibility as an end-point on long term outcome. International Journal of Cardiology, 2019, 277, 110-117.	1.7	12
67	Differences in the upslope of the precordial body surface ECG T wave reflect right to left dispersion of repolarization in the intact human heart. Heart Rhythm, 2019, 16, 943-951.	0.7	26
68	Catheter ablation for fascicular ventricular tachycardia: A systematic review. International Journal of Cardiology, 2019, 276, 136-148.	1.7	9
69	Left atrial scarring and conduction velocity dynamics: Rate dependent conduction slowing predicts sites of localized reentrant atrial tachycardias. International Journal of Cardiology, 2019, 278, 114-119.	1.7	11
70	Automated detection of repetitive focal activations in persistent atrial fibrillation: Validation of a novel detection algorithm and application through panoramic and sequential mapping. Journal of Cardiovascular Electrophysiology, 2019, 30, 58-66.	1.7	34
71	Inflammatory Biomarkers in Atrial Fibrillation. Current Medicinal Chemistry, 2019, 26, 837-854.	2.4	25
72	Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. International Journal of Cardiology, 2018, 260, 82-87.	1.7	20

#	ARTICLE	IF	CITATIONS
73	Validation of a novel mapping system and utility for mapping complex atrial tachycardias. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 395-403.	1.7	18
74	Does presence of left ventricular contractile reserve improve response to cardiac resynchronization therapy? An updated meta-analysis. <i>International Journal of Cardiology</i> , 2018, 252, 224-228.	1.7	4
75	Duration of hospital admission, need of on-demand analgesia and other peri-procedural and short-term outcomes in sub-cutaneous vs. transvenous implantable cardioverter-defibrillators. <i>International Journal of Cardiology</i> , 2018, 258, 133-137.	1.7	7
76	Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention. <i>Heart</i> , 2018, 104, 1529-1535.	2.9	20
77	Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis. <i>Europace</i> , 2018, 20, 89-96.	1.7	14
78	Catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis: a systematic review. <i>Europace</i> , 2018, 20, 682-691.	1.7	60
79	Cause-of-death analysis in patients with cardiac resynchronization therapy with or without a defibrillator: a systematic review and proportional meta-analysis. <i>Europace</i> , 2018, 20, 481-491.	1.7	15
80	Temporal pattern/episode duration-based classification of atrial fibrillation as paroxysmal vs. persistent: is it time to develop a more integrated prognostic score to optimize management?. <i>Europace</i> , 2018, 20, f288-f298.	1.7	14
81	Do women benefit equally as men from the primary prevention implantable cardioverter-defibrillator?. <i>Europace</i> , 2018, 20, 897-901.	1.7	28
82	Impact of QTc formulae in the prevalence of short corrected QT interval and impact on probability and diagnosis of short QT syndrome. <i>Heart</i> , 2018, 104, 502-508.	2.9	24
83	Biological therapies targeting arrhythmias: are cells and genes the answer?. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 237-249.	3.1	0
84	A Novel Mapping System for Panoramic Mapping of the Left Atrium. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 124-134.	3.2	79
85	Empowerment of athletes with cardiac disorders: a new paradigm. <i>Europace</i> , 2018, 20, 1243-1251.	1.7	13
86	Procedural and quality assessment data on catheter ablation for fascicular ventricular tachycardia. <i>Data in Brief</i> , 2018, 21, 2376-2378.	1.0	1
87	P5773 Atrial fibrillation catheter ablation in patients with hypertrophic cardiomyopathy: multi-centre experience and application of HCM-Risk SCD score to predict ablation outcome. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
88	Interrupted versus uninterrupted novel oral anticoagulant peri-implantation of cardiac device: A single-center randomized prospective pilot trial. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 1476-1480.	1.2	8
89	Catheter ablation for atrial fibrillation on uninterrupted direct oral anticoagulants: A safe approach. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 1001-1009.	1.2	6
90	Characterization of drivers maintaining atrial fibrillation: Correlation with markers of rapidity and organization on spectral analysis. <i>Heart Rhythm</i> , 2018, 15, 1296-1303.	0.7	33

#	ARTICLE	IF	CITATIONS
91	Cochrane corner: adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. <i>Heart</i> , 2018, 104, 1993-1994.	2.9	3
92	Association of catheter ablation for atrial fibrillation with mortality and stroke: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2018, 266, 136-142.	1.7	32
93	Risk Stratification in Brugada Syndrome: Current Status and Emerging Approaches. <i>Arrhythmia and Electrophysiology Review</i> , 2018, 7, 79.	2.4	23
94	Cryoablation of paroxysmal atrial fibrillation displayed the same results as radiofrequency despite anatomical variants of pulmonary veins. <i>Europace</i> , 2017, 19, euw277.	1.7	1
95	Results from a multicentre comparison of cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: is cryoablation more reproducible?. <i>Europace</i> , 2017, 19, euw080.	1.7	108
96	Subclavian crush syndrome AND subcutaneous ICD in primary prevention patients. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 717-718.	1.5	2
97	Sex-specific outcomes with addition of defibrillation to resynchronisation therapy in patients with heart failure. <i>Heart</i> , 2017, 103, 753-760.	2.9	21
98	Temporal Trends Over a Decade of Defibrillator Therapy for Primary Prevention in Community Practice. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 666-673.	1.7	14
99	Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	4.8	36
100	Is it time to loosen the restrictions on athletes with cardiac disorders competing in sport?. <i>British Journal of Sports Medicine</i> , 2017, 51, 1056-1057.	6.7	6
101	Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1669-1678.	2.8	56
102	Adenosine-guided pulmonary vein isolation versus conventional pulmonary vein isolation in patients undergoing atrial fibrillation ablation: An updated meta-analysis. <i>International Journal of Cardiology</i> , 2017, 227, 151-160.	1.7	7
103	Call for joint informed consent in athletes with inherited cardiac conditions. <i>Open Heart</i> , 2017, 4, e000516.	2.3	2
104	Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. <i>The Cochrane Library</i> , 2017, 2017, CD005154.	2.8	12
105	The Benefit of Cardiac Resynchronization Therapy Is Not Hindered by the Number of Comorbidities. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2096-2097.	2.8	4
106	Brugada syndrome is associated with scar and endocardial involvement: Insights from high-density mapping with the Rhythmia mapping system. <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 773.e1-773.e4.	0.5	5
107	Panoramic atrial mapping with basket catheters: A quantitative analysis to optimize practice, patient selection, and catheter choice. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 1423-1432.	1.7	24
108	The unfinished issue of ischaemic stroke and embolic events during catheter ablation of atrial fibrillation. <i>Europace</i> , 2017, 19, 881-881.	1.7	14

#	ARTICLE	IF	CITATIONS
109	Dual-site right ventricular pacing in patients undergoing cardiac resynchronization therapy: Results of a multicenter propensity-matched analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 1113-1120.	1.2	1
110	Impact of an Age-Adjusted Co-morbidity Index on Survival of Patients With Heart Failure Implanted With Cardiac Resynchronization Therapy Devices. <i>American Journal of Cardiology</i> , 2017, 120, 1158-1165.	1.6	12
111	Atrial fibrillation monitoring to reduce thromboembolic risk: Selecting the patient and the monitoring device. <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 547-549.	0.5	0
112	A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator. <i>International Journal of Cardiology</i> , 2017, 228, 280-285.	1.7	45
113	Brugada syndrome is associated with scar and endocardial involvement: Insights from high-density mapping with the Rhythmia mapping system. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2017, 36, 773.e1-773.e4.	0.2	2
114	Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women Data From a Multicenter French Registry. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	46
115	Ventricular stimulus site influences dynamic dispersion of repolarization in the intact human heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H545-H554.	3.2	20
116	Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. <i>Heart</i> , 2016, 102, 1533-1543.	2.9	89
117	The ABC risk score for patients with atrial fibrillation. <i>Lancet, The</i> , 2016, 388, 1979-1980.	13.7	0
118	Outcomes after cryoballoon or radiofrequency ablation for persistent atrial fibrillation: a multicentric propensity-score matched study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 47, 133-142.	1.3	25
119	Letter by Providencia and Lambiase Regarding Article, "Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death". <i>Circulation</i> , 2016, 133, e459.	1.6	1
120	Ventricular Arrhythmia Burden in Patients With Heart Failure and Cardiac Resynchronization Devices: The Importance of Renal Function. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 1328-1336.	1.7	4
121	Long-Term Results of Triventricular Versus Biventricular Pacing in Heart Failure. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 825-835.	3.2	13
122	Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification. <i>American Journal of Cardiology</i> , 2016, 118, 1225-1232.	1.6	8
123	Letter by Providencia and Lambiase Regarding Article, "Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction". <i>Circulation</i> , 2016, 133, e691.	1.6	7
124	Persistent Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2699-2700.	2.8	1
125	Endocardite de dispositivos, revisão com base na experiência de um centro. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 351-358.	0.5	2
126	Exercise restrictions for patients with inherited cardiac conditions: Current guidelines, challenges and limitations. <i>International Journal of Cardiology</i> , 2016, 209, 234-241.	1.7	21

#	ARTICLE	IF	CITATIONS
127	Outcomes after cryoablation vs. radiofrequency in patients with paroxysmal atrial fibrillation: impact of pulmonary veins anatomy. <i>Europace</i> , 2016, 18, 1343-1351.	1.7	64
128	Do we need further clinical-effectiveness estimates to support the use of primary prevention implantable cardioverter-defibrillators in New York Heart Association class III patients?. <i>International Journal of Cardiology</i> , 2016, 203, 184-186.	1.7	2
129	Authors' reply. <i>Europace</i> , 2015, 17, 1456-1456.	1.7	0
130	Prediction of Nonarrhythmic Mortality in Primary Prevention Implantable Cardioverter-Defibrillator Patients With Ischemic and Nonischemic Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2015, 1, 29-37.	3.2	13
131	Transvenous Implantable Cardioverter-Defibrillator (ICD) Lead Performance: A Meta-Analysis of Observational Studies. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	56
132	Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review. <i>Arquivos Brasileiros De Cardiologia</i> , 2015, 105, 519-26.	0.8	27
133	Impact of Free Thyroxine on the Outcomes of Left Atrial Ablation Procedures. <i>American Journal of Cardiology</i> , 2015, 116, 1863-1868.	1.6	19
134	Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. <i>Europace</i> , 2015, 17, 174-186.	1.7	64
135	Is There Still a Role for Complex Fractionated Atrial Electrogram Ablation in Addition to Pulmonary Vein Isolation in Patients With Paroxysmal and Persistent Atrial Fibrillation?. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1017-1029.	4.8	76
136	Comparison between radiofrequency with contact force-sensing and second-generation cryoballoon for paroxysmal atrial fibrillation catheter ablation: a multicentre European evaluation. <i>Europace</i> , 2015, 17, 718-724.	1.7	135
137	Universal Definition of Myocardial Infarction: Clinical Insights. <i>Cardiology</i> , 2015, 131, 13-21.	1.4	1,946
138	Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	28
139	Padrão de Brugada tipo 1 induzido pela febre. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 287.e1-287.e7.	0.5	4
140	Additional value of associating aortic valve calcification to coronary calcium as a gatekeeper for coronary tomography angiography. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 61.	1.7	1
141	Encerramento percutâneo de foramen ovale patente – registo da prevenção da embolia cerebral paradoxal. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 151-157.	0.5	2
142	Utilização de cardioversores desfibriladores implantáveis em desportistas: revisão sistemática. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 411-419.	0.5	2
143	Higher contact-force values associated with better mid-term outcome of paroxysmal atrial fibrillation ablation using the SmartTouch [®] catheter. <i>Europace</i> , 2015, 17, 56-63.	1.7	41
144	Contact-force guided radiofrequency vs. second-generation balloon cryotherapy for pulmonary vein isolation in patients with paroxysmal atrial fibrillation--a prospective evaluation. <i>Europace</i> , 2015, 17, 225-231.	1.7	117

#	ARTICLE	IF	CITATIONS
145	Does minimally invasive also stand for minimal patient risk? Lessons from an upper gastrointestinal endoscopy. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204048-bcr2014204048.	0.5	0
146	Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead. <i>Heart</i> , 2014, 100, 349-350.	2.9	2
147	Risk Stratification of Nonvalvular Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 222-223.	1.7	0
148	Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. <i>Heart</i> , 2014, 100, 324-335.	2.9	75
149	'Green light': watch it twice.... <i>Europace</i> , 2014, 16, 540-540.	1.7	0
150	Real-time assessment of bidirectional block during pulmonary vein cryoablation. <i>Europace</i> , 2014, 16, 1256-1256.	1.7	0
151	Real-time assessment of pulmonary vein disconnection during cryoablation of atrial fibrillation: can it be 'achieved' in almost all cases?. <i>Europace</i> , 2014, 16, 826-833.	1.7	37
152	Improving risk stratification in non-ST-segment elevation myocardial infarction with combined assessment of GRACE and CRUSADE risk scores. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 681-689.	1.6	6
153	Real-time Contact Force Sensing for Pulmonary Vein Isolation in the Setting of Paroxysmal Atrial Fibrillation: Procedural and 1-Year Results. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 130-137.	1.7	146
154	Can cardiac computed tomography predict cardiovascular events in asymptomatic type-2 diabetics?: results of a long term follow-up. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 2.	1.7	14
155	A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: Comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. <i>Thrombosis Research</i> , 2014, 134, 1253-1264.	1.7	48
156	Pulmonary embolism risk stratification: where are we heading?. <i>European Respiratory Journal</i> , 2014, 43, 298-300.	6.7	2
157	Atrial fibrillation in acute pulmonary embolism: prognostic considerations. <i>Emergency Medicine Journal</i> , 2014, 31, 308-312.	1.0	36
158	Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. <i>Europace</i> , 2014, 16, 1137-1144.	1.7	79
159	Which method of left atrium size quantification is the most accurate to recognize thromboembolic risk in patients with non-valvular atrial fibrillation?. <i>Cardiovascular Ultrasound</i> , 2014, 12, 28.	1.6	33
160	Post-acute management of the acquired long QT syndrome. <i>Postgraduate Medical Journal</i> , 2014, 90, 348-358.	1.8	17
161	Financial impact of adopting implantable loop recorder diagnostic for unexplained syncope compared with conventional diagnostic pathway in Portugal. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 63.	1.7	7
162	Meta-Analysis of the Influence of Chronic Kidney Disease on the Risk of Thromboembolism Among Patients With Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2014, 114, 646-653.	1.6	63

#	ARTICLE	IF	CITATIONS
163	Mean platelet volume is associated with the presence of left atrial stasis in patients with non-valvular atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 40.	1.7	23
164	Atrial fibrillation, elevated troponin, ischemic stroke and adverse outcomes: understanding the connection. <i>Clinical Research in Cardiology</i> , 2013, 102, 701-711.	3.3	16
165	Contrast-enhanced multidetector computed tomography: A new prognosticator in acute pulmonary embolism?. <i>Revista Portuguesa De Cardiologia</i> , 2013, 32, 839-840.	0.5	0
166	Letter to the Editorâ€” When to implant an ICD following a myocardial infarction?. <i>Heart Rhythm</i> , 2013, 10, e78.	0.7	0
167	The Role of Echocardiography in Thromboembolic Risk Assessment of Patients with Nonvalvular Atrial Fibrillation. <i>Journal of the American Society of Echocardiography</i> , 2013, 26, 801-812.	2.8	35
168	Early Repolarization and Arrhythmia Death. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2315-2316.	2.8	0
169	Stroke prediction with an adjusted R-CHA2DS2VASc score in a cohort of patients with a Myocardial Infarction. <i>Thrombosis Research</i> , 2013, 132, 293-299.	1.7	30
170	The benefit of implantable cardioverter defibrillator programming in MADIT-RIT: more for less?. <i>Europace</i> , 2013, 15, 1229-1230.	1.7	2
171	Chronic renal disease is associated with stroke and thromboembolism in atrial fibrillation independently from gender. <i>International Journal of Cardiology</i> , 2013, 168, 3106-3107.	1.7	4
172	Evaluation of left atrial deformation to predict left atrial stasis in patients with non-valvular atrial fibrillation â€” a pilot-study. <i>Cardiovascular Ultrasound</i> , 2013, 11, 44.	1.6	26
173	Cardiac troponin I: Prothrombotic risk marker in non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 167, 877-882.	1.7	24
174	Encerramento percutÃ¢neo do apÃ¢ndice auricular esquerdo para profilaxia de tromboembolismo na fibrilhaÃ¢o auricular em doentes com contraÃ¢ndicaÃ¢o ou falÃ¢ncia da hipocoagulaÃ¢o oral: experiÃ¢ncia de um serviÃ¢o. <i>Revista Portuguesa De Cardiologia</i> , 2013, 32, 461-471.	0.5	13
175	Troponin rise and poor outcome in patients presenting to the ED with short-duration atrial fibrillation. <i>American Journal of Emergency Medicine</i> , 2013, 31, 1147-1148.	1.6	0
176	Troponin rise in patients with atrial fibrillation: A marker of adverse prognosis and increased thromboembolic risk. <i>International Journal of Cardiology</i> , 2013, 168, 4889.	1.7	6
177	Percutaneous closure of the left atrial appendage for prevention of thromboembolism in atrial fibrillation for patients with contraindication to or failure of oral anticoagulation: A single-center experience. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2013, 32, 461-471.	0.2	8
178	Clinical correlates of early repolarization and J wave patternsâ€” are they proarrhythmic on their own?. <i>Journal of Electrocardiology</i> , 2013, 46, 73-74.	0.9	0
179	Chronic kidney disease: One step further in the refinement of risk stratification of atrial fibrillation and impact on the choice of anticoagulant. <i>Thrombosis Research</i> , 2013, 132, e158-e160.	1.7	0
180	Encerramento percutÃ¢neo do apÃ¢ndice auricular esquerdo para profilaxia de tromboembolismo na fibrilhaÃ¢o auricular. <i>Revista Portuguesa De Cardiologia</i> , 2013, 32, 311-323.	0.5	2

#	ARTICLE	IF	CITATIONS
181	The Use of the Chronic Kidney Disease Epidemiology Collaboration Equation and Global Cardiovascular Risk Assessment in Patients with Atrial Fibrillation. <i>Cardiology</i> , 2013, 124, 220-221.	1.4	1
182	Decreased Glomerular Filtration Rate and Markers of Left Atrial Stasis in Patients with Nonvalvular Atrial Fibrillation. <i>Cardiology</i> , 2013, 124, 3-10.	1.4	31
183	Letter by Providencia et al Regarding Article, "Atrial Fibrillation and the Risk of Ischemic Stroke: Does It Still Matter in Patients With a CHA ₂ -DS ₂ -VASc Score of 0 or 1?". <i>Stroke</i> , 2013, 44, e38.	2.0	3
184	Left ventricular mass as a discriminator of left atrial appendage thrombus in persistent atrial fibrillation: promise or over-enthusiasm?. <i>European Heart Journal Cardiovascular Imaging</i> , 2013, 14, 299-299.	1.2	0
185	Fever outperforms flecainide test in the unmasking of type 1 Brugada syndrome electrocardiogram. <i>Europace</i> , 2013, 15, 394-394.	1.7	15
186	Nesidioblastosis: an undescribed cause of transient loss of conscience in young adults. <i>Europace</i> , 2013, 15, 1506-1506.	1.7	2
187	Adjusting treatment to pulmonary vein rare anatomic variants: a box lesion for the ablation of atrial fibrillation in a patient with an atypical common inferior trunk. <i>Europace</i> , 2013, 15, 1420-1420.	1.7	4
188	Too ill for an implantable cardioverter defibrillator?. <i>Europace</i> , 2013, 15, 1226-1226.	1.7	1
189	Early repolarization patterns and the role of additional proarrhythmic triggers. <i>Europace</i> , 2013, 15, 482-485.	1.7	13
190	Early discharge and outpatient treatment of patients admitted for acute pulmonary embolism. <i>European Respiratory Journal</i> , 2013, 41, 486-487.	6.7	0
191	Pulmonary embolism risk stratification. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 896-898.	1.0	4
192	A Review on State-of-the-Art Data Regarding Safe Early Discharge Following Admission for Pulmonary Embolism: What Do We Know?. <i>Clinical Cardiology</i> , 2013, 36, 507-515.	1.8	20
193	Risk Stratification of Patients with Early Repolarization—Still an Unresolved Matter!. <i>Annals of Noninvasive Electrocardiology</i> , 2013, 18, 210-211.	1.1	0
194	The prevalence of left atrial appendage thrombus and spontaneous echocardiographic contrast is positively correlated with the CHADS ₂ and CHA ₂ -DS ₂ -VASc scores. <i>European Journal of Neurology</i> , 2013, 20, e84.	3.3	0
195	Excluding the Presence of Left Atrial Thrombus Before Pulmonary Vein Isolation: "primum non nocere". <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, E3-5.	1.7	0
196	Is More Aggressive Prevention of Coronary Artery Disease Required for Patients With Early Repolarization Syndrome?. <i>Circulation Journal</i> , 2013, 77, 1642.	1.6	1
197	Cardiovascular disease: thinking beyond atherosclerosis. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013009348-bcr2013009348.	0.5	0
198	Holiday Heart Syndrome Revisited after 34 Years. <i>Arquivos Brasileiros De Cardiologia</i> , 2013, 101, 183-9.	0.8	49

#	ARTICLE	IF	CITATIONS
199	Atypical atrial myxoma pending to the left atrial appendage: a diagnostic challenge. <i>BMJ Case Reports</i> , 2013, 2013, bcr2012007850-bcr2012007850.	0.5	1
200	Infecção recorrente em apresentação tardia de taquicardia ventricular polimórfica catecolaminérgica. <i>Arquivos Brasileiros De Cardiologia</i> , 2013, 100, e4-e7.	0.8	1
201	Mean corpuscular volume and red cell distribution width as predictors of left atrial stasis in patients with non-valvular atrial fibrillation. <i>American Journal of Cardiovascular Disease</i> , 2013, 3, 91-102.	0.5	9
202	Early Repolarization and Sudden Cardiac Death Due to an Acute Coronary Event. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, e116; author reply e117-8.	4.8	0
203	Manchester triage in acute pulmonary embolism: can it unmask the grand impersonator?. <i>Emergency Medicine Journal</i> , 2012, 29, e6-e6.	1.0	7
204	ACHTUNG-Rule: a new and improved model for prognostic assessment in myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012, 1, 320-336.	1.0	9
205	Mitral regurgitation during a myocardial infarction – New predictors and prognostic significance at two years of follow-up. <i>Acute Cardiac Care</i> , 2012, 14, 27-33.	0.2	7
206	Cardioversion safety in patients with nonvalvular atrial fibrillation. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 597-602.	1.0	19
207	Possible refinement of clinical thromboembolism assessment in patients with atrial fibrillation using echocardiographic parameters. <i>Europace</i> , 2012, 14, 36-45.	1.7	64
208	Should We Rely on Risk Assessment by the CHADS2 Score in Patients With Non-Valvular Atrial Fibrillation Undergoing Direct Current Cardioversion?. <i>American Journal of Cardiology</i> , 2012, 110, 468-469.	1.6	0
209	Is there a need for adjusting the results of the recent meta-analysis on the novel oral anticoagulants in atrial fibrillation to the baseline CHADS2 score?. <i>International Journal of Cardiology</i> , 2012, 159, 161-162.	1.7	3
210	High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2913-2913.	3.8	2
211	LR – PED Rule: Low Risk Pulmonary Embolism Decision Rule – A new decision score for low risk Pulmonary Embolism. <i>Thrombosis Research</i> , 2012, 130, 327-333.	1.7	26
212	Thoracic aortic aneurysm causing platypnoea and dorsalgia. <i>BMJ Case Reports</i> , 2012, 2012, bcr0220125879-bcr0220125879.	0.5	0
213	Non-Hodgkin's lymphoma presenting as a mediastinal mass in a 38-year-old patient with superior vena cava syndrome and extreme fatigue owing to left atrium and right ventricle outflow tract compression: the applicability of strain imaging. <i>BMJ Case Reports</i> , 2012, 2012, bcr0220125880-bcr0220125880.	0.5	0
214	Perforation of the right ventricle during cardiac resynchronisation therapy upgrade not related to a coexisting persistent left superior vena cava. <i>BMJ Case Reports</i> , 2012, 2012, bcr2012006299-bcr2012006299.	0.5	0
215	Impending paradoxical embolism with a thrombus crossing a patent foramen ovale. <i>BMJ Case Reports</i> , 2012, 2012, bcr2012006662-bcr2012006662.	0.5	5
216	Thromboembolic Risk in Atrial Flutter Resembles Non-Valvular Atrial Fibrillation (Insights from) Tj ETQq0 0 0 rgBT /Overlock 1Q Tf 50 62 T	1.6	3

#	ARTICLE	IF	CITATIONS
217	Challenging pulmonary embolism - A new generation of oral anticoagulants. <i>Journal of Thoracic Disease</i> , 2012, 4, 244-6.	1.4	2
218	Risk stratification of patients with atrial fibrillation: Biomarkers and other future perspectives. <i>World Journal of Cardiology</i> , 2012, 4, 195.	1.5	7
219	A CHADS(2) score of zero is not necessarily associated to a low risk of thromboembolic events. <i>American Journal of Cardiovascular Disease</i> , 2012, 2, 150-1.	0.5	0
220	Transient loss of consciousness in young adults. <i>International Journal of Cardiology</i> , 2011, 152, 139-143.	1.7	14
221	Thirteen square centimetre mass causing syncope in a patient with device related infective endocarditis. <i>BMJ Case Reports</i> , 2011, 2011, bcr1020114943-bcr1020114943.	0.5	0
222	Multidetector CT of rare isolated partial anomalous pulmonary venous return. <i>BMJ Case Reports</i> , 2011, 2011, bcr1020103381-bcr1020103381.	0.5	3
223	Importance of Manchester Triage in acute myocardial infarction: impact on prognosis. <i>Emergency Medicine Journal</i> , 2011, 28, 212-216.	1.0	16
224	Corrected ASD: case closed?. <i>BMJ Case Reports</i> , 2011, 2011, bcr0120113714-bcr0120113714.	0.5	0
225	Telangiectasia hereditária hemorrágica: causa rara de hipertensão pulmonar?. <i>Arquivos Brasileiros De Cardiologia</i> , 2010, 94, e94-e96.	0.8	4
226	Headache and cardiovascular disease: old symptoms, new proposals. <i>Future Cardiology</i> , 2010, 6, 703-723.	1.2	1
227	Cardiac MDCT assessment of compression of the left main stem by a dilated pulmonary trunk. <i>Revista Portuguesa De Cardiologia</i> , 2010, 29, 893-4.	0.5	0
228	Screening for warning signs of sudden cardiac death in the young: the SCD-SOS questionnaire. <i>Revista Portuguesa De Cardiologia</i> , 2010, 29, 1191-205.	0.5	2
229	Pulmonary hypertension in patients with ostium secundum atrial septal defect--is it related to echocardiographic complexity?. <i>Revista Portuguesa De Cardiologia</i> , 2009, 28, 1087-96.	0.5	3
230	Aquarium sign in sepsis. <i>European Heart Journal Cardiovascular Imaging</i> , 2008, 9, 336-337.	1.2	2
231	External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	2.8	0
232	Defining electrocardiographic criteria to differentiate non-type 1 Brugada ECG variants from normal incomplete RBBB patterns in the young SCD-SOS cohort. <i>Journal of Cardiovascular Electrophysiology</i> , 0, , .	1.7	1